Triage of HPV positivity in a high HIV prevalence setting: A prospective cohort study comparing visual triage methods and HPV genotype restriction in Botswana.
8-type HPV genotype restriction
cervical dysplasia
cervical screening
colposcopy
human immunodeficiency virus (HIV)
human papillomavirus (HPV)
low- and middle-income countries (LMICs)
triage
visual inspection with acetic acid (VIA)
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
10 Nov 2023
10 Nov 2023
Historique:
revised:
08
09
2023
received:
26
06
2023
accepted:
12
10
2023
medline:
11
11
2023
pubmed:
11
11
2023
entrez:
11
11
2023
Statut:
aheadofprint
Résumé
Guidelines for effective triage following positive primary high-risk human papillomavirus (HPV) screening in low- and middle-income countries with high human immunodeficiency virus (HIV)-prevalence have not previously been established. In the present study, we evaluated the performance of three triage methods for positive HPV results in women living with HIV (WLHIV) and without HIV in Botswana. We conducted baseline enrollment of a prospective cohort study from February 2021 to August 2022 in South-East District, Botswana. Non-pregnant women aged 25 or older with an intact cervix and no prior diagnosis of cervical cancer were systematically consented for enrollment, with enrichment of the cohort for WLHIV. Those who consented completed a questionnaire and then collected vaginal self-samples for HPV testing. Primary HPV testing for 15 individual genotypes was conducted using Atila AmpFire® HPV assay. Those with positive HPV results returned for a triage visit where all underwent visual inspection with acetic acid (VIA), colposcopy, and biopsy. Triage strategies with VIA, colposcopy and 8-type HPV genotype restriction (16/18/31/33/35/45/52/58), separately and in combination, were compared using histopathology as the gold standard in diagnosing cervical intraepithelial neoplasia (CIN) 2 or worse (CIN2+). Among 2969 women enrolled, 1480 (50%) tested HPV positive. The cohort included 1478 (50%) WLHIV; 99% were virologically suppressed after a mean of 8 years on antiretroviral therapy. In total, 1269 (86%) women had histopathology data for analysis. Among WLHIV who tested positive for HPV, 131 (19%) of 688 had CIN2+ compared with 71 (12%) of 581 in women without HIV. Screening by 8-type HPV genotype restriction was more sensitive as triage to detect CIN2+ in WLHIV 87.79% (95% CI: 80.92-92.85) and women without HIV 85.92% (95% CI: 75.62-93.03) when compared with VIA (WLHIV 62.31% [95% CI: 53.39-70.65], women without HIV 44.29% [95% CI: 32.41-56.66]) and colposcopy (WLHIV 70.77% [95% CI: 62.15-78.41], women without HIV 45.71% [95% CI: 33.74-58.06]). However, 8-type HPV genotype restriction had low specificity in WLHIV of 30.88% (95% CI: 27.06-34.90) and women without HIV 37.06% (95% CI: 32.85-41.41). These results were similar when CIN3+ was used as the outcome. When combining 8-type HPV genotype restriction with VIA as the triage strategy, there was improved specificity to detect CIN2+ in WLHIV of 81.65% (95% CI: 78.18-84.79) but dramatically reduced sensitivity of 56.15% (95% CI: 47.18-64.84). Eight-type HPV genotype restriction is a promising component of effective triage for HPV positivity. However, novel triage strategies in LMICs with high HIV prevalence may be needed to avoid the trade-off between sensitivity and specificity with currently available options. This study is registered on Clinicaltrials.gov no. NCT04242823, https://clinicaltrials.gov/ct2/show/NCT04242823.
Banques de données
ClinicalTrials.gov
['NCT04242823']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : 1K08CA271949
Pays : United States
Informations de copyright
© 2023 International Federation of Gynecology and Obstetrics.
Références
Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-e203.
Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 1997;337:1343-1910.
Heard I, Cubie HA, Mesher D, Sasieni P, for the MACH-1 Study Group. Characteristics of HPV infection over time in European women who are HIV-1 positive. BJOG. 2013;120(1):41-49.
Denny LA, Franceschi S, de Sanjose S, Heard I, Moscicki AB, Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine. 2012;30:F168-F174.
Stelzle D, Tanaka LF, Lee KK, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Global Health. 2021;9(2):E161-E169.
Bruni L, Serrano B, Roura E, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 2022;10(8):e1115-e1127.
Kelly H, Jaafar I, Chung M, et al. Diagnostic accuracy of cervical cancer screening strategies for high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) among women living with HIV: a systematic review and meta-analysis. eClinicalMedicine. 2022;53:101645.
Shastri S, Temin S, Almonte M, et al. Secondary prevention of cervical cancer: ASCO resource-stratified guideline update. JCO Global Oncol. 2022;8:e2200217.
Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189-197.
World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. 2021. Accessed 04 April 2023. https://www.who.int/publications/i/item/9789240030824
Baena A, Mesher D, Salgado Y, et al. Performance of visual inspection of the cervix with acetic acid (VIA) for triage of HPV screen-positive women: results from the ESTAMPA study. Int J Cancer. 2022;152:1-12. doi:10.1002/ijc.34384
Toliman PJ, Kaldor JM, Badman SG, et al. Performance of clinical screening algorithms comprising point-of-care HPV-DNA testing using self-collected vaginal specimens, and visual inspection of the cervix with acetic acid, for the detection of underlying high-grade squamous intraepithelial lesions in Papua New Guinea. Papillomavirus Res. 2018;6:70-76.
Luckett R, Mogowa N, Li HJ, et al. Performance of two-stage cervical cancer screening strategies utilizing primary hrHPV testing for women living with HIV. Obstet Gynecol. 2019;134(4):840-849.
Kelly HA, Chikandiwa A, Sawadogo B, et al. Diagnostic accuracy of cervical cancer screening and screening−triage strategies among women living with HIV-1 in Burkina Faso and South Africa: a cohort study. PLoS Med. 2021;18(3):e1003528.
World Health Organization. Comprehensive Cervical Cancer Control: A Guide to Essential Practice. 2nd ed. WHO Press; 2014.
Kahesa C, Thomsen LT, Linde DS, et al. Comparison of human papillomavirus-based cervical cancer screening strategies in Tanzania among women with and without HIV. Int J Cancer. 2023;152:686-696.
Botha MH, Van der Merwe FH, Snyman LC, Dreyer GJ, Visser C, Dreyer G. Utility of extended HPV genotyping as primary cervical screen in an unscreened population with high HIV co-infection. J Lower Gen Tract Dis. 2023;27:212-216.
Mwenda V, Bor JP, Nyangasi M, et al. Integrating human papillomavirus testing as a point-of-care service using GeneXpert platforms: findings and lessons from a Kenyan pilot study (2019-2020). PloS One. 2023;18(5):e0286202.
Elliot T, Kohler R, Monare B, et al. Performance of vaginal self-sampling for HPV testing among women living with HIV in Botswana. J STD AIDS. 2019;30(12):1169-1176.